NIH Launches New Web Site for Parents on Medical Research Studies for Children
A new Web site from the National Institutes of Health (NIH), "Children and Clinical Studies," offers parents and health care providers an insider's guide to children's medical research.
NIH Launches New Web Site for Parents on Medical Research Studies for Children
Award-winning video clips feature children, parents discussing clinical studies
BETHESDA, MD · October 6, 2008 /PRNewswire/ — From asthma and cancer treatments to vaccines, research in children saves lives and improves their health and well-being. A new Web site from the National Institutes of Health (NIH), "Children and Clinical Studies" (www.ChildrenAndClinicalStudies.nhlbi.nih.gov <http://www.ChildrenAndClinicalStudies.nhlbi.nih.gov> ), offers parents and health care providers an insider's guide to children's medical research. The Web site combines information about how clinical studies in youth are conducted with award-winning video of children, parents, and healthcare providers discussing the rewards and challenges of participating in research.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
